Evropska unija - slovenščina - EMA (European Medicines Agency)

allergan pharmaceuticals international ltd - prašek trebušne slinavke - eksocrine pankreasne pomanjkljivosti - digestivi, vklj. encimi - zdravljenje s pankreatičnimi encimi pri eksokrinalni insuficienci pankreasa zaradi cistične fibroze ali drugih stanj (e. kronični pankreatitis, post pancreatectomy ali rak trebušne slinavke). enzepi je navedeno v dojenčki, otroci, mladostniki in odrasli.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale 10 av -

Evropska unija - slovenščina - EMA (European Medicines Agency)

pari pharma gmbh - tobramycin - cystic fibrosis; respiratory tract infections - antibacterials za sistemsko uporabo , aminoglycoside antibacterials - zdravilo vantobra je indicirano za zdravljenje kronične pljučne infekcije zaradi pseudomonas aeruginosa pri bolnikih, starih 6 let ali več, s cistično fibrozo (cf). upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibacterials za sistemsko uporabo, - vantobra je označen za upravljanje kronično pljučno okužbo, zaradi pseudomonas aeruginosa pri bolnikih, starih 6 let in več, s cistično fibrozo (cf). upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intervet international -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kemofarmacija d.d. - prašek za inhaliranje - kolistin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prašek in vehikel za raztopino za inhaliranje - kolistin

Evropska unija - slovenščina - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastiki - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.